Cover Image
市場調查報告書

末梢神經鞘腫瘤 (神經纖維肉瘤) :開發中產品分析

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017

出版商 Global Markets Direct 商品編碼 362363
出版日期 內容資訊 英文 137 Pages
訂單完成後即時交付
價格
Back to Top
末梢神經鞘腫瘤 (神經纖維肉瘤) :開發中產品分析 Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017
出版日期: 2017年06月30日 內容資訊: 英文 137 Pages
簡介

本報告提供末梢神經鞘腫瘤 (神經纖維肉瘤) 治療藥的開發情形相關調查,提供您開發中產品概要,各臨床實驗階段的產品概要,主要企業及藥物簡介,開發中產品的最新趨勢,及最新消息/新聞稿等資訊。

簡介

  • 調查範圍

末梢神經鞘腫瘤 (神經纖維肉瘤)的概要

治療藥的開發

  • 開發中產品的概要
  • 開發中產品比較分析

末梢神經鞘腫瘤 (神經纖維肉瘤):企業開發中的治療藥

末梢神經鞘腫瘤 (神經纖維肉瘤):大學/機關研究中的治療藥

末梢神經鞘腫瘤 (神經纖維肉瘤):開發中產品概況

  • 臨床階段的產品
  • 初期階段的產品

末梢神經鞘腫瘤 (神經纖維肉瘤):企業開發中的產品

末梢神經鞘腫瘤 (神經纖維肉瘤):大學/機關研究中的產品

末梢神經鞘腫瘤 (神經纖維肉瘤的)治療藥的開發企業

  • Bexion Pharmaceuticals, LLC.
  • EpiZyme, Inc.
  • Merck & Co., Inc.
  • Millennium Pharmaceuticals, Inc.
  • Novartis AG
  • Plexxikon Inc.
  • Synta Pharmaceuticals Corp.
  • Vyriad

末梢神經鞘腫瘤 (神經纖維肉瘤):治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

末梢神經鞘腫瘤 (神經纖維肉瘤):最近的開發平台趨勢

末梢神經鞘腫瘤 (神經纖維肉瘤):產品開發的里程碑

  • 主要消息和新聞稿

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC9477IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017, provides an overview of the Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline landscape.

Malignant peripheral nerve sheath tumors (MPNSTs) are sarcomas which originate from peripheral nerves or from cells associated with the nerve sheath, such as Schwann cells, perineural cells, or fibroblasts. Symptoms include lump or swelling in the in the soft tissue, numbness, burning or having that pins and needles feeling, weakness in the affected muscles and dizziness or loss of balance. Treatment includes surgery, radiotherapy and chemotherapy.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II and Phase I stages are 7 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecules, respectively.

Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Overview
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Companies Involved in Therapeutics Development
  • Bexion Pharmaceuticals LLC
  • EpiZyme Inc
  • Merck & Co Inc
  • Millennium Pharmaceuticals Inc
  • Novartis AG
  • Pfizer Inc
  • Plexxikon Inc
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Drug Profiles
  • axitinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • BXQ-350 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • everolimus - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • ganetespib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Oncolytic Virus to Target CD46 and SLC5A5 for Oncology - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • pembrolizumab - Drug Profile
  • R&D Progress
  • pexidartinib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • sapanisertib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Small Molecules to Inhibit BRD4 for Malignant Peripheral Nerve Sheath Tumors - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • tazemetostat - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Product Development Milestones
  • Featured News & Press Releases
  • Dec 26, 2013: UTSW study identifies potential therapeutic target for incurable, rare type of soft-tissue cancer
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer

List of Tables

  • Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products under Development by Universities/Institutes, H1 2017
  • Products under Development by Companies, H1 2017
  • Products under Development by Universities/Institutes, H1 2017
  • Number of Products by Stage and Target, H1 2017
  • Number of Products by Stage and Mechanism of Action, H1 2017
  • Number of Products by Stage and Route of Administration, H1 2017
  • Number of Products by Stage and Molecule Type, H1 2017
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Bexion Pharmaceuticals LLC, H1 2017
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by EpiZyme Inc, H1 2017
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Merck & Co Inc, H1 2017
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Millennium Pharmaceuticals Inc, H1 2017
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Novartis AG, H1 2017
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Pfizer Inc, H1 2017
  • Peripheral Nerve Sheath Tumor (Neurofibrosarcoma) - Pipeline by Plexxikon Inc, H1 2017

List of Figures

  • Number of Products under Development for Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), H1 2017
  • Number of Products under Development by Companies, H1 2017
  • Number of Products by Top 10 Targets, H1 2017
  • Number of Products by Stage and Top 10 Targets, H1 2017
  • Number of Products by Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017
  • Number of Products by Routes of Administration, H1 2017
  • Number of Products by Stage and Routes of Administration, H1 2017
  • Number of Products by Molecule Types, H1 2017
  • Number of Products by Stage and Molecule Types, H1 2017
Back to Top